A claims program tied to generic-drug price-fixing settlements has a March 8, 2027 deadline. New York Attorney General Letitia James says the settlements total more than $96 million and cover purchases of more than 100 generic medicines. The court has preliminarily approved the distribution plan, which means this is an open claims process, but the program’s eligibility rules—not the headline alone—determine whether a purchase belongs in it.
The March 8, 2027 deadline belongs to a live claims program
James’s September 22 release says eligible consumers must submit claims by March 8, 2027. It directs consumers to the settlement administrator’s site and says the U.S. District Court for the District of Connecticut recently gave preliminary approval to the coalition’s plan to distribute money to consumers who overpaid for certain generic drugs.
That date is the submission deadline, not an assurance that a payment will be issued on March 8. A claims administrator has to review submissions under the court-approved process, and payment amounts can depend on eligible purchases, documentation rules and the number of valid claims. The state release does not promise an equal share to everyone who files.
The attorney general identifies a bipartisan coalition of 47 other attorneys general. Its announcement is a current state-government record of the deadline, while the administrator’s site provides the form and detailed process. Those are stronger references than advertisements offering to file a claim for a fee.
Four dates can appear in one claim notice: The submission date, purchase period and payment timing serve different purposes in a settlement record. See the four-date rule in The Settlement & Refund Recovery System.
The settlement concerns more than 100 generic medicines
The state says the litigation alleges that dozens of manufacturers conspired to inflate prices, limit competition and rig bids involving more than 100 generic drugs. The medicines span tablets, capsules, creams and ointments and include treatments for conditions ranging from infections and diabetes to cancer, epilepsy and HIV. That broad description is why an individual medicine name cannot be assumed to qualify without checking the official eligibility materials.
The release says the three underlying complaints were filed in 2016, 2019 and 2020 and involved different sets of products and defendants. Those older litigation dates do not make the claim notice stale: the current September 22 announcement pins the live distribution plan and the March 8, 2027 submission deadline. The relevant question is the current claims process, not the age of the alleged conduct.
Some price increases alleged by the coalition exceeded 1,000%, the state says, and it gives Digoxin as one example in which a manufacturer tripled the price. That historical example illustrates the allegations but does not establish a refund amount for a particular purchase. The eventual distribution follows the approved plan, not the most dramatic figure in the release.
The $96 million figure reflects settlements with Apotex and Heritage, Bausch and Lannett, and Glenmark Pharmaceuticals USA, according to the release. The states say those companies agreed to cooperate in continuing cases against other corporate defendants and executives. The program is therefore one part of a longer antitrust effort, not a conclusion to every allegation involving generic-drug pricing.
The three complaints were filed in 2016, 2019 and 2020. Those older litigation dates do not make the current claims window stale: the September 22, 2026 announcement records the recent preliminary approval and the March 8, 2027 deadline. The live question is whether a purchaser meets the administrator’s terms, not when the allegations first began.
James said consumers paid excessive amounts after companies colluded to raise prices. Her statement is an allegation-backed enforcement description; it does not change the standard for an individual claim. The official form asks for the facts the administrator needs, and the administrator decides whether a submission is valid.
Why the deadline and the purchase details should be kept together
Settlement notices often combine several dates: a purchase period, the deadline to submit, a deadline to dispute or exclude, and a possible distribution date. Treating them as interchangeable is a common source of mistakes. The confirmed March 8, 2027 date is specifically the consumer claim deadline described by New York’s attorney general.
The release says consumers may submit online, request a form from the claims administrator or use the contact information on the official settlement page. It is sensible to retain the confirmation received after a form is submitted, because that document identifies what was actually sent and when. It is not necessary to pay a third party to create a record the official program can create directly.
The verified present record is an open generic-drug settlement claims process with a March 8, 2027 deadline and more than $96 million in settlements. The central next fact is whether the official program’s purchase and consumer criteria match the particular claim, not a headline’s broad description of the case.
A simple file for settlement notices
A claims program is easier to follow when its deadline, confirmation and supporting records sit in one place. The administrator’s eligibility rules remain the controlling source for a particular submission.
The Settlement & Refund Recovery System includes a 5-tab Excel tracker, a source vault of 12 official places money sits and a step-by-step filing walkthrough.
See the claim-record worksheet in The Settlement & Refund Recovery System.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
